Cures for all presents a real focus for the next decade – but companies must be rewarded for their work.

A new computational tool could help improve the stability and predictability of ADCs.

GE and Alderley Park are teaming up in support of SMEs in Northern England.

Jane Osbourn talks about the potential of the UK's cell and gene therapy space.

How will the adoption of novel approaches to the development of excipients help overcome the challenges of poorly soluble APIs?

How will inhaled therapies evolve? Lei Mao at Recipharm gives his take on the future of these therapies.

"Moving beyond Cas9 may be the secret to reducing CRISPR’s off-target effects," says Garrett Rettig.

We must never forget unmet needs when developing new medicines.

Meet two companies that are advancing pharmaceutical development and manufacture.

Can new tools lower the hurdle of high manufacturing costs for cell and gene therapies?